Pascolizumab

Drug Profile

Pascolizumab

Alternative Names: Anti-IL-4 monoclonal antibody - GlaxoSmithKline; Anti-IL-4 monoclonal antibody - Protein Design Labs; Anti-interleukin-4 monoclonal antibody - GlaxoSmithKline; Anti-interleukin-4 monoclonal antibody - Protein Design Labs; SB 240683

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 09 May 2003 Discontinued - Phase-II for Asthma in USA (IV)
  • 15 Oct 2001 Phase-II clinical trials for Asthma in USA (IV) (NCT00024544)
  • 27 Apr 2001 A phase I study in patients with asthma has been added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top